# EDGAR Filing Document

**Accession Number:** 0001882782
**File Stem:** 0000950103-26-007273
**Filing Date:** 2026-5
**Character Count:** 20070
**Document Hash:** ec8c3e0deeaef6cba0c54ff310836524
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950103-26-007273.hdr.sgml**: 20260515

**ACCESSION NUMBER**: 0000950103-26-007273

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260515

**DATE AS OF CHANGE**: 20260515

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Odyssey Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001882782
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 863384382
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-95704
- **FILM NUMBER:** 26985991

**BUSINESS ADDRESS:**
- **STREET 1:** 51 SLEEPER STREET
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210
- **BUSINESS PHONE:** (212) 841-1000

**MAIL ADDRESS:**
- **STREET 1:** 51 SLEEPER STREET
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Jeito II S.L.P.
- **CENTRAL INDEX KEY:** 0002134396

**ORGANIZATION NAME:**
- **EIN:** 981767478
- **STATE OF INCORPORATION:** I0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 37 RUE DE LA VICTOIRE
- **CITY:** PARIS
- **PROVINCE COUNTRY:** I0
- **ZIP:** 75009
- **BUSINESS PHONE:** 33603354757

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 37 RUE DE LA VICTOIRE
- **CITY:** PARIS
- **PROVINCE COUNTRY:** I0
- **ZIP:** 75009

## Exhibit 99.1

**Exhibit 99.1**

**Joint Filing Agreement**

In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing of a Statement on Schedule 13D (including amendments thereto) with respect to the common stock of Odyssey Therapeutics, Inc. and further agree that this Joint Filing Agreement be included as an Exhibit thereto. In evidence thereof, the undersigned, being duly authorized, have executed this Joint Filing Agreement this 15<sup>th</sup> day of May, 2026.

---

| | |
|:---|:---|
| **JEITO II S.L.P.** | **JEITO II S.L.P.** |
| By: | /s/ Rafaele Tordjman |
|  | Rafaele Tordjman, CEO of Jeito Capital SAS acting as management company of Jeito II S.L.P. |

---

---

| | |
|:---|:---|
| **JEITO Capital SAS** | **JEITO Capital SAS** |
| By: | /s/ Rafaele Tordjman |
|  | Rafaele Tordjman, CEO |

---

---

| | |
|:---|:---|
| **Rafaele Tordjman** | **Rafaele Tordjman** |
| By: | /s/ Rafaele Tordjman |

---

---

| | |
|:---|:---|
| **Sabine Dandiguian** | **Sabine Dandiguian** |
| By: | /s/ Sabine Dandiguian |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**ODYSSEY THERAPEUTICS, INC.**

*(Name of Issuer)*

**COMMON STOCK, $0.0001 par value per share**

*(Title of Class of Securities)*

**—**

*(CUSIP Number)*

**Rafaele Tordjman**<br>37 rue de la Victoire<br>Paris I0 75009<br>33603354757

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**05/08/2026**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Jeito II S.L.P.** | Name of reporting person<br>**Jeito II S.L.P.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**I0** | Citizenship or place of organization<br>**I0** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**3690145.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**3690145.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**3690145.00** | Aggregate amount beneficially owned by each reporting person<br>**3690145.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**7.8%** | Percent of class represented by amount in Row (11)<br>**7.8%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** The percentage in row 13 is calculated based on 47,174,156 shares of common stock, reported to be outstanding in the Issuer's Form 424(b)(4) filed with the Securities and Exchange Commission on May 8, 2026.

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Jeito Capital SAS** | Name of reporting person<br>**Jeito Capital SAS** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**I0** | Citizenship or place of organization<br>**I0** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**3690145.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**3690145.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**3690145.00** | Aggregate amount beneficially owned by each reporting person<br>**3690145.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**7.8%** | Percent of class represented by amount in Row (11)<br>**7.8%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IA** | Type of Reporting Person (See Instructions)<br>**IA** | |

---

**Comment for Reporting Person:** The percentage in row 13 is calculated based on 47,174,156 shares of common stock, reported to be outstanding in the Issuer's Form 424(b)(4) filed with the Securities and Exchange Commission on May 8, 2026.

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Rafaele Tordjman** | Name of reporting person<br>**Rafaele Tordjman** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**I0** | Citizenship or place of organization<br>**I0** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**3690145.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**3690145.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**3690145.00** | Aggregate amount beneficially owned by each reporting person<br>**3690145.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**7.8%** | Percent of class represented by amount in Row (11)<br>**7.8%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** The percentage in row 13 is calculated based on 47,174,156 shares of common stock, reported to be outstanding in the Issuer's Form 424(b)(4) filed with the Securities and Exchange Commission on May 8, 2026.

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Sabine Dandiguian** | Name of reporting person<br>**Sabine Dandiguian** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**I0** | Citizenship or place of organization<br>**I0** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**3690145.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**3690145.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**3690145.00** | Aggregate amount beneficially owned by each reporting person<br>**3690145.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**7.8%** | Percent of class represented by amount in Row (11)<br>**7.8%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** The percentage in row 13 is calculated based on 47,174,156 shares of common stock, reported to be outstanding in the Issuer's Form 424(b)(4) filed with the Securities and Exchange Commission on May 8, 2026.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
COMMON STOCK, $0.0001 par value per share

**(b) Name of Issuer:**
ODYSSEY THERAPEUTICS, INC.

**(c) Address of Issuer's Principal Executive Offices:**
51 SLEEPER STREET, SUITE 800, BOSTON, MA, 02210

**Item 4. Purpose of Transaction**

Jeito II S.L.P. acquired the shares of common stock as described in this Schedule 13D for investment purposes in the regular course of its business. Jeito Capital SAS, as the management company of Jeito II S.L.P., may be deemed to be a beneficial owner, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Act"), of any securities held by Jeito II S.L.P. Rafaele Tordjman, as Chief Executive Officer of Jeito Capital SAS, and Sabine Dandiguian, as Managing Director of Jeito Capital SAS, may be deemed to be beneficial owners, for purposes of Section 13(d) of the Act, of any securities of the Issuer beneficially owned by Jeito Capital SAS. The Reporting Persons intend to review their investment in the Issuer on a continuing basis. Depending on market conditions, liquidity requirements, the continuing evaluation of the business and prospects of the Issuer and other factors, the Reporting Persons may dispose of or acquire additional shares of common stock of the Issuer. Ksenija Pavletic, who is the General Partner and Chief Commercial Officer at Jeito Capital SAS, is a director of the Issuer. The Reporting Persons, either directly or indirectly through Ms. Pavletic, may engage in discussions from time to time with the Board, the Issuer's management or the Issuer's other stockholders, including discussions that may relate to the items described in clauses (a) through (j) of Item 4 of Schedule 13D. Except as set forth in this Item 4 or Item 6 below, the Reporting Persons have no present plans or proposals that relate to or that would result in any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D.

**Item 5. Interest in Securities of the Issuer**

**(a)**
Jeito II S.L.P. holds 3,690,145 shares of common stock, representing approximately 7.8% of the Issuer's outstanding shares of common stock, based upon 47,174,156 shares of common stock reported to be outstanding in the Issuer's Form 424(b)(4) filed with the Securities and Exchange Commission on May 8, 2026. Jeito Capital SAS is the management company of Jeito II S.L.P. As a result, Jeito Capital SAS shares power to direct the vote and disposition of the shares held by Jeito II S.L.P. and may be deemed to be the beneficial owner of the shares held by Jeito II S.L.P. Rafaele Tordjman, as Chief Executive Officer of Jeito Capital SAS, and Sabine Dandiguian, as Managing Director of Jeito Capital SAS, may be deemed to be beneficial owners, for purposes of Section 13(d) of the Act, of any securities of the Issuer beneficially owned by Jeito Capital SAS.

**(b)**
Rows 7 through 10 of each Reporting Person's cover page to this Schedule 13D set forth the number of shares of common stock as to which such Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or direct the disposition and are incorporated by reference.

**(c)**
The response to Item 3 of this Schedule 13D is incorporated herein by reference.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

On April 7, 2026, in connection with the Issuer's IPO, Jeito II S.L.P. entered into a lock-up agreement (the "Lock-Up Agreement") with J.P. Morgan Securities LLC, TD Securities (USA) LLC and Cantor Fitzgerald & Co., as representatives of the several underwriters. Pursuant to the Lock-Up Agreement, Jeito II S.L.P. has agreed that, subject to certain exceptions, it will not, for a period of 180 days following May 7, 2026, the date of the Issuer's prospectus filed pursuant to Rule 424(b)(4) with the SEC, without the prior written consent of the representatives, (i) offer, sell, contract to sell, pledge, grant any option, right or warrant to purchase, purchase any option or contract to sell, lend or otherwise transfer or dispose of any shares of common stock, or any options or warrants to purchase any shares of common stock, or any securities convertible into, exchangeable for or that represent the right to receive shares of common stock (collectively, "Lock-Up Securities"), including without limitation any such Lock-Up Securities then owned or thereafter acquired, (ii) engage in any hedging or other transaction or arrangement or transfer of any of the economic consequences of ownership, in whole or in part, directly or indirectly, of any Lock-Up Securities, whether any such transaction or arrangement (or instrument provided for thereunder) would be settled by delivery of common stock or other securities, in cash or otherwise, (iii) make any demand for or exercise any right with respect to the registration of any Lock-Up Securities or (iv) otherwise publicly announce any intention to engage in or cause any action, activity, transaction or arrangement described above. The foregoing description of the Lock-Up Agreement does not purport to be complete and is qualified in its entirety by reference to such, which form is filed as an exhibit and incorporated herein by reference.

Jeito II S.L.P. is a party to that certain Investors' Rights Agreement, as amended and restated on June 16, 2025, by and among the Issuer and certain of its stockholders named therein (the "IRA"). Pursuant to the terms of the IRA, beginning 180 days after May 7, 2026, the effective date of the registration statement for the Issuer's IPO, holders of a majority of the then-outstanding Registrable Securities (as defined therein) have the right to require the Issuer to file a Form S-1 registration statement to register at least 40% of the then-outstanding Registrable Securities with an anticipated aggregate offering price of at least $10 million, subject to customary terms and conditions. At any time the Issuer is eligible to use a Form S-3 registration statement, the holders who are party to the IRA and who collectively hold at least 25% of then-outstanding Registrable Securities have the right to require the Issuer to file a registration statement on Form S-3 to register outstanding Registrable Securities of such holders having an anticipated aggregate offering price of at least $5 million, subject to customary terms and conditions. Under the IRA, holders of Registrable Securities are entitled to piggyback registration rights, subject to customary terms and conditions. The foregoing description of the IRA does not purport to be complete and is qualified in its entirety by reference to such, which is filed as an exhibit and incorporated herein by reference.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Jeito II S.L.P.

**Signature:** /s/ Rafaele Tordjman

**Name/Title:** Rafaele Tordjman, CEO of Jeito Capital SAS acting as management company of Jeito II S.L.P.

**Date:** 05/15/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Jeito Capital SAS

**Signature:** /s/ Rafaele Tordjman

**Name/Title:** Rafaele Tordjman, CEO

**Date:** 05/15/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Rafaele Tordjman

**Signature:** /s/ Rafaele Tordjman

**Name/Title:** Rafaele Tordjman

**Date:** 05/15/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Sabine Dandiguian

**Signature:** /s/ Sabine Dandiguian

**Name/Title:** Sabine Dandiguian

**Date:** 05/15/2026